Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why [Yahoo! Finance]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Yahoo! Finance
The company is developing its lead product candidate, azenosertib, a potentially first-in-class WEE1 inhibitor, as a monotherapy and in combination with other therapies for treating different types of cancer indications, including solid tumors and ovarian cancer. In June 2024, the FDA placed a partial clinical hold on three studies evaluating azenosertib for three different cancer indications. The phase I ZN-c3-001 dose-escalation study evaluated azenosertib for treating solid tumors, while the phase II ZN-c3-005 DENALI study investigated azenosertib in platinum-resistant ovarian cancer (PROC). The phase II ZN-c3-004 TETON study evaluated azenosertib for the treatment of uterine serous carcinoma. The regulatory body placed a partial clinical hold on all these studies after two patients in the DENALI study died due to presumed sepsis. This could have been the primary reason for the stock's decline during the said time. Image Source: Zacks Investment Research Top-line data
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswire
- Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its price target lowered by analysts at Guggenheim from $12.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of AzenosertibGlobeNewswire
ZNTL
Earnings
- 11/12/24 - Beat
ZNTL
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/13/24 - Form 3
- ZNTL's page on the SEC website